Fundraising FoxZylembio
1 known investors
Find your way into Zylembio
Sign up to see every warm intro you have to Zylembio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Zylembio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Zylem Biosciences develops Metabolic Redox Modulators (MRMs), a patented platform of drug candidates targeting the SR-B1 receptor to treat cancer, cardiovascular disease, and other age-related conditions. The company leverages fifteen years of research from Northwestern University to create therapeutics that induce metabolic dysfunction in disease cells while sparing healthy cells.
Founders & leadership
ST
Shad ThaxtonMD, PhD
KM
Kaylin McMahonPhD
PB
Philip Bligh
Board
JV
Jay VenkatesanMD, MBA
LG
Leo GordonMD
Investors · 1
Frequently asked questions
- What does Zylembio do?
- Zylem Biosciences develops Metabolic Redox Modulators (MRMs), a patented platform of drug candidates targeting the SR-B1 receptor to treat cancer, cardiovascular disease, and other age-related conditions. The company leverages fifteen years of research from Northwestern University to create therapeutics that induce metabolic dysfunction in disease cells while sparing healthy cells.
- Who founded Zylembio?
- Zylembio was founded by Shad Thaxton.
- Who are Zylembio's investors?
- Zylembio's investors include Portal Innovations.